Trials / Completed
CompletedNCT00044005
Safety and Tolerability Study of Drug to Treat Schizophrenia
A Randomized, Open-Label, Dose-Blinded, Multicenter, 6-Month Study of Safety and Tolerability of 3 Dose Levels of SM-13496 (Lurasidone) in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone 20 mg | Lurasidone 20mg oral tablet taken once daily for 6-months |
| DRUG | Lurasidone 40 mg | Lurasidone 40mg oral tablets taken once daily |
| DRUG | Lurasidone 80mg | Lurasidone 80mg oral tablet taken once daily |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2003-11-01
- Completion
- 2003-11-01
- First posted
- 2002-08-20
- Last updated
- 2014-04-17
- Results posted
- 2011-05-19
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00044005. Inclusion in this directory is not an endorsement.